2 results match your criteria: "23303Sinai Hospital of Baltimore[Affiliation]"
J Cardiovasc Pharmacol Ther
January 2021
Sinai Center for Thrombosis Research, 23303Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD, USA.
Introduction: Tegaserod, an orally active, potent 5-hydroxytryptamine-4 serotonin receptor agonist, was previously indicated for irritable bowel syndrome but was voluntarily withdrawn due to potential cardiovascular side effects. In vitro studies suggested that tegaserod increased platelet aggregation, but these results were not reproduced or were inconclusive. We sought to assess ex vivo effects of tegaserod on platelet aggregation.
View Article and Find Full Text PDFJ Intensive Care Med
March 2021
Outcomes After Critical Illness and Surgery Group, 1466Johns Hopkins University, Baltimore, MD, USA.
Background And Objectives: Impaired physical functioning is common and long lasting after an intensive care unit (ICU) admission. The 6-minute walk test (6MWT) is a validated and widely used test of functional capacity. This systematic review synthesizes existing data in order to: (1) evaluate 6-minute walk distance (6MWD) in meters over longitudinal follow-up after critical illness, (2) compare 6MWD between acute respiratory distress syndrome (ARDS) versus non-ARDS survivors, and (3) evaluate patient- and ICU-related factors associated with 6MWD.
View Article and Find Full Text PDF